KRAS and pancreatic neoplasm: EL-TGFα mice have been employed in combination with p53 loss (Greten et al., 2001; Schreiner et al., 2003) to generate a model of advanced pancreatic cancer with hallmark genetic features (loss of p16, inactivation of Cdkn2a) reminiscent in human disease and, in combination with mutant Kras, development of CPN that resembles human IPMN (Siveke et al., 2007).